tbuckley/cabot-search huggingface dataset:
Registration
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Determination of Selenium in the Environment and in Biological Material
Authors: Ewa M. Bem
Journal: Environmental Health Perspectives (1981)

This paper reviews the following problems, sampling, decomposition procedures and most important analytical methods used for selenium determination, e.g., neutron activation analysis, atomic absorption spectrometry, gas-liquid chromatography, spectrophotometry, fluorimetry, and x-ray fluorescence. This review covers the literature mainly from 1975 to 1977.
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.
Authors: B. Y. Karlan, A. M. Oza, V. L. Hansen, G. E. Richardson, D. M. Provencher, P. Ghatage, M. Tassoudji, D. E. Stepan, D. M. Weinreich, I. B. Vergote
Journal: Journal of Clinical Oncology (2010)

5000 Background: AMG 386 is an investigational peptide-Fc fusion protein that inhibits angiogenesis by neutralizing the interaction between the Tie2 receptor and angiopoietin 1 and 2. We evaluated the safety and efficacy of AMG 386 combined with paclitaxel in recurrent ovarian cancer. Methods: Pts with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer were randomized 1:1:1 to receive paclitaxel at 80 mg/m2 IV QW (3 on/1 off) plus AMG 386 at 10 mg/kg (Arm A), 3 mg/kg (Arm B) or placebo (Arm C) IV QW, until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response per RECIST (ORR), CA-125 response (per GCIG), safety and pharmacokinetics. Results: 161 pts were randomized (Arms A/B/C, n=53/53/55). Efficacy results are shown in the table. Notable adverse events included peripheral edema (Arm A/B/C, 71/51/29%; grade ≥3, 4/6/4%), hypokalemia (21/15/5%; grade ≥3, 12/11/4%), thromboembolic events (arterial, 2/2/0%, all grade ≥3; venous, 8/8/11%; grade ≥3, 6/6/9%) and hypertension (8/8/5%, no grade 3). There were no bowel perforations in AMG 386 treated patients; no deaths on study were considered treatment-related. 3 of 92 treated pts had non-neutralizing anti-AMG 386 antibodies. AMG 386 Cmax and Cmin values were dose-proportional and similar to those observed in prior monotherapy studies. Conclusions: In this study, AMG 386 combined with weekly paclitaxel was tolerable with a manageable safety profile distinct from VEGF inhibitors and showed promising evidence of antitumor activity with a dose-response effect. Further studies are warranted. Arm A* (n = 53) AMG 386 10 mg/kg Arm B* (n = 53) AMG 386 3 mg/kg Arm C* (n = 55) placebo Primary endpoint Median PFS (80% CI), mos 7.2 (5.7, 7.5) 5.7 (5.2, 7.8) 4.6 (2.0, 5.5) Cox model,** HR (80% CI) vs. Arm C 0.76 (0.57, 1.02) p=0.23 0.75 (0.56, 1.00) p=0.21 0.76 (0.59, 0.98), p=0.17 Dose response, ordered log-rank test,** p value 0.074 Secondary endpoint ORR (CR + PR), % 37 19 27 CA-125 response, % 71 58 28 * All arms received weekly paclitaxel. ** Stratified by prior anti-VEGF therapy, progression on or within 6 mos of last chemotherapy regimen. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen Amgen Amgen, Schering-Plough Amgen
Evaluation of the Effectiveness of Mass Screening for Uterine Cancer in Japan: The Potential Years of Life Lost
Authors: Tetsuo Kuroishi, Kaoru Hirose, Suketami Tominaga
Journal: Environmental Health Perspectives (1990)

To evaluate the effectiveness of mass screening for uterine cancer in Japan, we compared the changes in the age-adjusted rates of potential years of life lost (PYLL) due to uterine cancer between 1969 and 1972 to 1973 through 1977 between the high coverage-rate (intensively screened) areas and the comparable control areas. The percent reduction in the average age-adjusted rate of PYLL due to uterine cancer and the years of life saved per 100,000 females were greater in the high coverage-rate areas than in the control areas. These results suggested that mass screening programs for uterine cancer contribute to saving years of life.
Error in Byline
Authors: Laura Iglesias-Girard, Simon Roy, Hugo Chapdelaine, Delphine Désy, Danielle Bouffard, Deana Funaro
Journal: JAMA Dermatology (2020)

Caren Droesch, MD; Mytrang Hoang Do, BS; Maria DeSancho, MD, MSc; Eun-Ju Lee, MD; Cynthia Magro, MD; Joanna Harp, MD
Reply
Authors: Lindsay D. Plank, John L. McCall, Edward J. Gane
Journal: Hepatology (2015)

Potential conflict of interest: Dr. Gane advises and is on the speakers’ bureau for Gilead, Merck, and AbbVie. He advises Janssen. We appreciate the interest shown in our study1 by Dr. Bharadwaj and colleagues. They refer to the guidelines issued by the American Society for Parenteral and Enteral Nutrition for the clinical evaluation of nutritional status based on “medical, nutrition, and medication histories; physical examination; anthropometric measurements; and laboratory data.”2 However, such clinical evaluation is problematic in end‐stage liver disease, as has been highlighted by others.3 The primary objective of the assessment of nutritional status is the identification of malnutrition2 or what is essentially muscle wasting or protein depletion. We sought to identify malnutrition in our patients using a robust and objective technique, namely, neutron activation analysis. Our assessment of protein status was based on the gold standard method of whole‐body protein stores measured by neutron activation, related to normative data in a way not dissimilar to use of the fifth percentile as a threshold for identification of low muscle mass based on normative data for mid‐upper arm circumference or area.4 We would point out that neutron activation measurements of body protein were used for objective validation of the widely accepted clinical evaluation tool subjective global assessment5 and that total‐body protein estimated from a multicompartment model was used for external validation of the clinical assessment approach devised by Morgan et al.4 for patients with cirrhosis. The duration of preoperative nutritional supplementation reflects the variable and unpredictable waiting time for liver transplantation. The 600 mL/day (at 1 kcal/mL) feed we prescribed fits within the European Society of Parenteral and Enteral Nutrition guidelines, and it could be argued that the extended duration should have provided a greater opportunity for differences to be demonstrated between the immunonutrition and control groups. We do not have an explanation for the lack of benefit from immunonutrition in this patient population, but it is unlikely to reflect a type II error because there was no divergence in favor of immunonutrition in any of the laboratory or clinical endpoints.
Community-acquired Acinetobacter calcoaceticus var anitratus pneumonia
Authors: G. L. Goodhart
Journal: JAMA (1977)

Two patients had community-acquired<i>Acinetobacter calcoaceticus</i>var<i>anitratus</i>pneumonia. Both patients were alcoholic and one was cirrhotic. One patient died and the other received two weeks of gentamicin therapy and survived. Misinterpretation of the sputum Gram stain delayed diagnosis and institution of proper therapy in both cases. In addition to organisms sensitive to penicillins such as<i>Neisseria</i>or<i>Haemophilus, Acinetobacter</i>must be considered in the differential diagnosis of community-acquired Gramnegative coccobacillary pneumonia. (<i>JAMA</i>238:1516-1518, 1977)
Arterial chemoembolization with microencapsulated anticancer drug. An approach to selective cancer chemotherapy with sustained effects
Authors: T. Kato
Journal: JAMA (1981)

Selective intra-arterial infusion of ethylcellulose microcapsules containing mitomycin exerts its therapeutic effects through infarction and sustained drug action—ie, chemoembolization. Sixty primary or secondary carcinomas in the kidney, liver, urinary bladder, prostate, cervix, vagina, sigmoid colon, Douglas' pouch, and bone were treated with single or repeated chemoembolizations using microcapsules delivered through percutaneous catheterization as a preoperative or palliative measure. Substantial tumor reduction of greater than 30% in measurable maximum diameter was found in 65% of the tumors; pain relief occurred in 80% and hemostasis in 100%. Preoperative chemoembolization remarkably facilitated radical surgery in 18 (82%) of 22 patients. The summed response rate was 77%. Systemic toxic effects were mild, and all patients tolerated the treatment. Though the follow-up periods are less than two years, 37 patients are alive with or without tumor. (<i>JAMA</i>1981;245:1123-1127)
Clinical Spectroscopy
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Questions and Answers
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Education and training
Authors: S Smith, N Roberts
Journal: Thorax (2009)

Objectives We have established a clinical research fellows training initiative (CRFTI) to attract, encourage and support clinical trainees interested in undertaking postgraduate research.The CRFTI aims to (1) match potential fellows with appropriate supervisors to their research interests; (2) support the process of writing grant/fellowship applications; (3) advise on regulatory, intellectual, statistical and financial considerations; and (4) guide interview technique.Methods We planned a session on ''Higher Degrees'' as part of the Respiratory Specialist Registrar NW Thames training programme.A pre-session questionnaire (Pre-Q) was sent to all trainees in order to tailor the session to their needs.Questions asked whether trainees planned to do research, their reasons, advice they needed and, for those who had undertaken research, what advice they would give.Pre-Q informed us to direct initial talks on funding opportunities, choosing supervisors, deanery issues and job prospects.Feedback was undertaken with a post-session questionnaire (Post-Q) to guide future talks and role of CRFTI.Results 18/44 trainees (41%) responded to the Pre-Q where 39% (7/ 18) had previously undertaken and 62% (11/18) were planning research.Responses are grouped into themes listed by the number of times cited (table 1).Conclusions Trainees require the necessary information at an early stage of their career to provide them with an informed decision to undertake research.Importantly, following our session, several trainees were considering undertaking research having previously felt they lacked ''academic capability''.The CRFTI is actively supporting 9/34 attending trainees (26%) towards research fellowships and will develop a website resource.We hope the initial experiences of our focused initiative may be a helpful model for other academic institutions to consider.
Uroporphyria in the uroporphyrinogen decarboxylase-deficient mouse: Interplay with siderosis and polychlorinated biphenyl exposure
Authors: M Franklin
Journal: Hepatology (2002)

Several methods have been used to develop rodent models with the hepatic manifestations of porphyria cutanea tarda (PCT). Acute iron administration or mutations of the hemochromatosis gene (Hfe) have been used to generate hepatic siderosis, a nearly uniform finding in PCT. Heterozygosity for a null mutation at the uroporphyrinogen decarboxylase (Uro-D+/−) locus has been developed to mimic familial PCT in humans. This study examines the interplay of these 2 genetic risk factors and their influence, alone and combined with polychlorinated-biphenyl exposure. Neither an Hfe-null mutation nor iron-dextran administration alone or in combination with polychlorinated biphenyl exposure was porphyrinogenic in a 3-week model using mice wild-type at the Uro-D locus. Homozygosity for an Hfe-null mutation significantly elevated hepatic iron but not to the extent seen with parenteral iron-dextran administration. Homozygosity for an Hfe-null mutation but not iron-dextran administration was porphyrinogenic in animals heterozygous for the Uro-D mutation. Polychlorinated biphenyls were also porphyrinogenic in these animals. Uroporphyria in Uro-D+/− animals was exacerbated by combinations of the homozygous Hfe-null mutation and polychlorinated biphenyls and iron-dextran and polychlorinated biphenyls. In all cases in which uroporphyria developed, a greater degree of experimental uroporphyria was seen in female animals. All elevated hepatic uroporphyrin concentrations were accompanied by depressed uroporphyrinogen decarboxylase activity and the presence of a factor in cytosol that inhibits recombinant human uroporphyrinogen decarboxylase. In conclusion, the expression of the uroporphyric phenotype, dependent on the susceptibility imparted by a genetic mutation, provides a uniquely facile model for dissecting the molecular pathogenesis of the disease. (HEPATOLOGY 2002;36:805-811.)
Diagnostic and therapeutic technology assessment. Percutaneous lumbar diskectomy for herniated disks
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thiopurine methyltransferase Genotype Is Not a Risk Factor for Secondary Malignant Neoplasias after Treatment for Childhood Acute Lymphoblastic Leukemia on Berlin-Frankfurt-Muenster Protocols.
Authors: Martin Stanulla, Elke Schaeffeler, Anja Moericke, Gunnar Cario, Michel Eichelbaum, Hansjoerg Riehm, Karl Welte, Martin Schrappe, Matthias Schwab
Journal: Blood (2006)
Störungen des Trieb- und Affektlebens (Die parapathischen Erkrankungen).
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Florence
Authors: John C. Mannone
Journal: Annals of Internal Medicine (2019)

Ad Libitum5 March 2019FlorenceJohn C. Mannone, MSJohn C. Mannone, MSNiota, Tennessee (J.C.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-3306 Audio Reading - “Florence” Audio. Virginia Hood, MD, reads "Florence," by J.C. Mannone. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail His bones ache, bands of clouds pushing infrom the Atlantic—deep low, eye of a hurricanejust offshore. Charlie, a thin scruffy man slipsinto the examination room, the nurse smiles.But his lips are pursed until Doctor Jim knocksbefore he enters. His eyes perhaps not as blueas normal, his hair silvery under fluorescentlights jiggling like lightning after the door shuts.He flips the pages on his clipboard, rattlesa few numbers with 20-letter-long names.The patient fidgets uncomfortably, suddenlyblaring demand for the results. The doctor pauses,The silence, so loud ... Author, Article, and Disclosure InformationAffiliations: Niota, Tennessee (J.C.M.)Current Author Address: John C. Mannone, MS; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “Florence” Audio. Virginia Hood, MD, reads "Florence," by J.C. Mannone. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 5 March 2019Volume 170, Issue 5Page: 350KeywordsAdenocarcinomaBoneFloodingNursesPainStorms ePublished: 5 March 2019 Issue Published: 5 March 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Telemedicine
Authors: R. K. Grigsby
Journal: JAMA (1995)

<h3>To the Editor.</h3> —I read with great interest the article by Drs Perednia and Allen.<sup>1</sup>I agree that there are many unresolved issues related to the implementation of telemedicine in the US health care system. However, the authors state, "In almost every telemedicine project, teleconsultation accounts for less than 25% of the use of the system. The majority of on-line time is used for medical education and administration." This is certainly not true for the Medical College of Georgia (MCG). From November 1991 through October 1994, a total of 355 telemedical clinical consultations were completed at the MCG across a wide range of medical specialties. Although physicians requesting consultations with MCG faculty can earn Category I continuing medical education credit by participating in the teleconsultation process, the system is used for actual medical consultation. Continuing education might be described best as "value added." The authors might also wish to
Obituary Listing
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal